Illumina, Inc. is an American company. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in San Diego, California.
| Revenue (TTM) | $4.49B |
| Gross Profit (TTM) | $3.05B |
| EBITDA | $1.16B |
| Operating Margin | 21.10% |
| Return on Equity | 32.30% |
| Return on Assets | 8.67% |
| Revenue/Share (TTM) | $29.57 |
| Book Value | $18.80 |
| Price-to-Book | 13.17 |
| Price-to-Sales (TTM) | 8.82 |
| EV/Revenue | 8.62 |
| EV/EBITDA | 27.96 |
| Quarterly Earnings Growth (YoY) | -9.40% |
| Quarterly Revenue Growth (YoY) | 9.40% |
| Shares Outstanding | $151.00M |
| Float | $150.50M |
| % Insiders | 0.21% |
| % Institutions | 107.42% |
Volatility is currently expanding
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The new platform brings together advanced analysis, purpose-built AI, and curated biological data so researchers can move more quickly from complex genomic and multiomic data to actionable insight Included in the new platform, latest DRAGEN update expands access to Illumina's award-winning secondary analysis across supported cloud and standard computing environment SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today debuted the Illumina BioInsight Platform, the company's first unified software environment designed to help researchers turn complex genomic and multiomic data into meaningful biological evidence. By bringing together Illumina's analysis applications, purpose-built AI innovations, and curated data resources in one environment, the platform delivers flexibility and accessibility, while reducing the need to assemble and manage separate informatics tools as research questions evolve.
SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2026 following the close of market on Thursday, October 29, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.
In a rare disease research dataset, SpliceAI2 identified 17% more disease-relevant variants compared to other splicing models Illumina's genomic AI models now collectively enable researchers to identify 2x as many variants with predicted biological impact SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today introduced SpliceAI2, a new genomic AI model designed to address one of the central challenges in genomics: understanding the functional consequences of genetic variation. SpliceAI2 helps researchers identify disease-relevant splice variants that otherwise may go unnoticed.
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).
Illumina (ILMN +0.04%) is building a deeper AI strategy around the biological data created by its sequencing technology. The Billion Cell Atlas, expanding drugmaker partnerships, and improving core business could create a new growth engine if Illumina can turn its scientific advantage into recurring commercial revenue.
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Regeneron (REGN) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?
Investors need to pay close attention to ILMN stock based on the movements in the options market lately.
ILMN's 94.9% YTD rally reflects strong sequencing growth, clinical adoption and a raised 2026 outlook despite China headwinds.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ILMN and any ticker you trade — then tracks every position and per-strategy win rate.
